Medical/Pharmaceuticals
SeromYx Systems and ACROBiosystems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
NEWARK, Del., Sept. 29, 2024 /PRNewswire/ -- SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, an innovative provider for life science solutions and tools, are excited to announce the release of their joint study on the comprehensive functional profiling of approv...
2024-09-29 21:00
2904
IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel（FucasoTM）in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif, Sept. 29, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentati...
2024-09-29 21:00
3484
New Beginnings, New Journey | Sanyou Opening of New 10,000-sqm Facility, Ushering in a New Era of Innovation for Bio Drugs
SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Sanyou Bio recently celebrated a prestigious move into its new 10,000-square-meter R&D building atShanghai headquarters. This is not just a change in physical location, but a qualitative leap in the company infrastructure. It marks a solid step forward for...
2024-09-28 20:00
5223
111, Inc. Announces Receipt of Notification from Nasdaq
SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced it has received a...
2024-09-28 05:00
4400
Concord Medical Reports Financial Results for the First Half of 2024
BEIJING, Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced its unaudited consolidated financial results for t...
2024-09-27 19:00
5363
IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentat...
2024-09-27 15:41
2377
Datasea Announces Fiscal Year 2024 Financial Results with Revenue 6.6x that of 2023 Primarily due to Growth of its 5G AI Business
The Total Value of 5G-AI Contracts Currently in Process Exceeds $100 MM BEIJING, Sept. 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based digital technology company focused on innovative high-tech intelligent acoustics and 5G AI multimodal digital t...
2024-09-26 21:45
5161
Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria
SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 has been granted the Breakthrough Therapy Designation (BTD) by National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN...
2024-09-26 15:10
16726
Mediwhale Secures $12 Million in Series A2 Funding to Drive Global Leadership in Cardiovascular and Metabolic Disease Management
SEOUL, South Korea, Sept. 25, 2024 /PRNewswire/ -- Mediwhale
2024-09-26 02:00
3631
The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA
CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned subsidiary, Claruvis Pharmaceutical Co., has received approval from the U.S. Food and Drug A...
2024-09-25 21:18
3140
Flat Medical Strengthens Market Leadership with Acquisition of InjeQ Assets, Including FDA-Designated Breakthrough Device IQ-Tip®
TAIPEI, Sept. 25, 2024 /PRNewswire/ -- Flat Medical, a leading innovator in medical technology, today announced its acquisition of key assets from InjeQ, including the FDA-designated breakthrough device, IQ-Tip®. This strategic move bolsters Flat Medical's leadership position in the medical devic...
2024-09-25 20:00
2820
Samsung Biologics launches development platforms for enhanced therapeutic efficacy
* Samsung Biologics showcases new innovative development platforms – S-AfuCHO TM and S-OptiChargeTM – at BioProcess International 2024 * New technology platforms to proactively address evolving industry trends and enable high-quality development INCHEON, South Korea, Sept. 25, 2024 /PRNewswire...
2024-09-25 19:00
2450
XtalPi Launches Computational Chemistry Software for Drug Discovery: XMolGen and XFEP
BOSTON and SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- Today, XtalPi announced the official launch of XFEP and XMolGen, two proprietary software products designed to accelerate and enhance the efficiency of drug discovery. Upon this launch, XtalPi will offer commercial licenses with flexible terms f...
2024-09-24 21:00
4869
LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners
SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio" or the "Company"), a Phase III-stage biotech company focused on the R&D of innovative antibody and fusion protein drugs for allergies and complement-mediated diseases, announced the completion of its Series B2 ...
2024-09-24 21:00
3724
Noul Demonstrates 'Expert-Level' AI Diagnostic Performance in Europe… Results from Spain's Carlos III Health Institute
* Study of 329 Patients in Europe Shows Superior Performance Compared to Microscopic Diagnosis * Sensitivity: 94.4%, Specificity: 97.2%, Agreement Rate: 92% YONGIN, South Korea, Sept. 24, 2024 /PRNewswire/ -- Noul Co., Ltd. (CEO: David Lim, hereafter referred to as "Noul") has proven the expe...
2024-09-24 21:00
2504
Bestqool Pro Series Iteration: Upgraded Design for Enhanced User Experience
NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Bestqool, a leading red light therapy
industry company, proudly presents the newest iteration of itsPro Series
2024-09-24 21:00
2030
Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Generation Immunotherapeutics Discovery
CAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™ ), announced today that it has entered into a strategic collaboration with Alkyon Therapeutics, Inc. (AlkyonTx), aSan Diego-based biotechnology ...
2024-09-24 20:00
1868
Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024
SHANGHAI, Sept. 23, 2024 /PRNewswire/ -- On September 14, 2024, BioCity presented interim clinical results on the safety and efficacy of its first-in-class antibody-drug conjugate (ADC) BC3195 targeting CDH3 (P-Cadherin) in a Phase I clinical trial at the European Society for Medical Oncology (ES...
2024-09-23 17:40
15649
WuXi Biologics Included in Hang Seng ESG 50 Index
HONG KONG, Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ESG 50 Index, making it the only pharmaceutical company selected this...
2024-09-23 17:30
2659
Professor Luo Min Appointed as Chairman of Spine Neurocardiology Interdisciplinary Professional Committee in China to Promote Development of Innovative Heart Disease Treatments
BEIJING, Sept. 23, 2024 /PRNewswire/ -- Professor Luo Min, Doctor of Medicine (MD), from Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital, was recently appointed as the Chairman of the National Association of Health Industry and Enterprise Management (NAHIE...
2024-09-23 15:06
2030
Week's Top Stories
Most Reposted
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 295 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 284 media titles]
2026-10-15 10:00SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 282 media titles]
2026-10-15 12:59
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 272 media titles]
2026-10-21 15:00
Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
29152
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
18894